Depressive Disorder and Anxiety Disorders Clinical Trial
Official title:
An Open Label, Randomised, Single Dose, Three-way Crossover Study to Investigate the Relative Bioavailability of Two Different Formulations of GSK163090 and the Effect of Food on the Pharmacokinetics of a Tablet Formulation in Healthy Male and Female Volunteers
The study will consist of a screening period, 3 treatment periods and a post-treatment follow-up. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01424384 -
Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic
|
Phase 1 | |
| Completed |
NCT00513565 -
A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00426608 -
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
|
Phase 1 | |
| Completed |
NCT01031186 -
First Time in Human Study
|
Phase 1 | |
| Completed |
NCT00435695 -
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males
|
Phase 1 | |
| Completed |
NCT00343707 -
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
|
Phase 2 | |
| Completed |
NCT01059591 -
First Study in Humans With GSK424887
|
Phase 1 | |
| Completed |
NCT01059578 -
First Study in Humans With GSK206136
|
Phase 1 | |
| Completed |
NCT00703547 -
A First Time in Human Study of GSK586529 in Healthy Volunteers
|
Phase 1 |